Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chembio Diagnostics has acquired a worldwide, non-exclusive sublicense from Bio-Rad Laboratories for patents relating to the human immunodeficiency virus, type 2, or HIV-2.
Subscribe to our email newsletter
Bio-Rad is the exclusive licensee of Institute Pasteur of Paris, France, under the HIV-2 patents. Under the terms of the sublicense, Chembio has obtained non-exclusive rights to certain HIV-2 patents from Bio-Rad, which will permit Chembio to manufacture and market a rapid test for both HIV-1 and HIV-2 on a worldwide basis under Chembio brands. Bio-Rad maintains rights to patents claiming the HIV-2 virus and various means to detect its presence in infected patients.
Norman Schwartz, president and CEO of Bio-Rad, said: “Bio-Rad continues to work with global partners to expand the range of available HIV diagnostic products. Granting a sublicense to Chembio for HIV-2 patents offers a new diagnostics option to the public health community.”